Study details
Enrolling now
HA-1 T TCR T Cell Immunotherapy for Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT IDNCT03326921ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
24
Study length
about 10 years
Ages
≤80
Locations
1 site in WA
About this study
This trial is testing a new treatment called HA-1 T cell immunotherapy in adults who have relapsed or refractory acute leukemia after a donor stem cell transplant. The treatment involves collecting and modifying donor cells to recognize HA-1 markers on leukemia cells, which are then infused back into the patient.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- 2.Undergo Biospecimen Collection
- 3.Undergo Bone Marrow Aspiration
PhasePhase 1
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Proportion of subjects who develop new or recurrent symptoms or signs of graft-versus-host disease
Procedures
diagnostic, biopsy
Body systems
Oncology